NEW AP107 Treatment Implication of ER-Positive and HER2-Positive Breast Cancer—The Critical Role of Pathologists
8:00–9:00 am
1.0 CME CREDITS
Breast cancer is a disease with significant clinical diversity, necessitating an individualized approach to its management. Of central importance to this decision-making is the evaluation of the predictive markers ER, PgR, and HER2 that are routinely utilized to help define treatment. Given the role of these predictive markers in determining therapy, assay results must be as accurate as possible. Various clinical, pathological and technical factors can affect the accurate testing of ER and HER2; knowing their presence and their roles in effecting the ER and HER2 results are critical for pathologists reporting these test results. Using cases of ER and HER2 testing as examples, this course will illustrate important issues encountered in correct interpretation of ER and HER2 in daily practice.
You will learn to:
- Explain the importance of standardized tissue handling in ER and HER2 testing
- Identify the critical elements required in ER and HER2 testing interpretation and reporting
- Utilize the reject criteria for ER and HER2 reporting and how to troubleshoot unexpected results
- Correlate other clinical and pathological information when evaluating ER and HER2 testing
Faculty
David G. Hicks, MD, FCAP
Ping Tang, MD, PhD, FCAP